Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on December 11, 2015. The report discloses a scientific publication regarding the company's lead drug candidate, CERC-501 (formerly LY2456302), a potent and selective oral kappa opioid receptor antagonist being developed to treat depression and substance use disorders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical research developments and does not contain financial statements or operational financial data.
Material Changes
The material event reported is the publication of a study in the December issue of the Journal of Pharmacology and Experimental Therapeutics. The study, conducted by researchers at Yale University School of Medicine and Eli Lilly and Company, demonstrated that CERC-501 achieves reproducible penetration of the blood-brain barrier and target engagement in healthy volunteers, as measured by positron emission tomography (PET) imaging.
Outlook and Risks
Management commentary is limited to the announcement of the study's positive findings regarding brain penetration and target engagement. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the standard regulatory disclaimers regarding the non-filing status of the press release information.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed study parameters and limitations.
- Confirm the current development status and regulatory pathway for CERC-501 following this publication.
- Review subsequent filings for any financial impact or funding requirements related to advancing the clinical program.
- Note that the registrant is Cerecor Inc., not Avalo Therapeutics, Inc., as indicated in the metadata request.